{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:14:15Z","timestamp":1772226855333,"version":"3.50.1"},"reference-count":29,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: To explore the application value of three novel serum markers, collagen X-type &lt;span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\"&gt;\u03b1&lt;\/span&gt;1 chain (COL10A1), gastrokine 2 (GKN2), and lipase F (LIPF), in the diagnosis of gastric cancer. Methods: Differential markers of gastric cancer were mined from public databases (TCGA, GTEx). From November 2022 to October 2024, 108 healthy people and patients with stomach cancer who underwent gastroscopy and pathological examinations at our hospital were chosen as research subjects. Among these patients, 60 had stomach cancer (28 in the early gastric cancer group and 32 in the advanced gastric cancer group), whereas 48 patients were in the healthy group. Receiver operating characteristic (ROC) curves were created to examine the relationship between the detection of gastric cancer and the serum levels of markers. Additionally, the application value of both the detection of new markers and the detection of conventional markers (PGI, PGII) in the diagnosis of gastric cancer was examined. Results: Three differential markers of gastric cancer (COL10A1, GKN2 and LIPF) were extracted from a public database. By detecting the levels of three markers in clinical blood samples, the AUC of the combined detection of the three markers (COL10A1+ GKN2 + LIPF 3MP) in the differentiating group (3MP vs PGR: 0.842 vs 0.841) and the early gastric cancer group (0.877 vs 0.843) was greater than that of PGR (PGI\/PGII). The combined conventional markers (PGI, PGII) and the combined detection of five markers (3MP+PGI + PGII, 5MP) had AUCs of 0.963 and 0.953, respectively. Conclusions: COL10A1, GKN2 and LIPF are very promising serum markers for the diagnosis of gastric cancer. The joint detection of the serum levels of these three novel markers and PGI and PGII has essential value for the early detection of gastric cancer.<\/jats:p>","DOI":"10.5937\/jomb0-59476","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:08:01Z","timestamp":1755846481000},"page":"301-309","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the clinical diagnostic efficacy of the novel serum markers lipase F, gastrokine 2 and the collagen X-type \u03b11 chain in gastric cancer"],"prefix":"10.5937","volume":"45","author":[{"given":"Fashe","family":"Wang","sequence":"first","affiliation":[{"name":"Ningbo Mingzhou Hospital, Department of General Surgery Zhejiang Province, Ningbo, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bai","family":"Li","sequence":"additional","affiliation":[{"name":"Fujian Medical University First Affiliated Hospital, Department of Gastroenterology, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangyin","family":"Li","sequence":"additional","affiliation":[{"name":"Fujian Medical University First Affiliated Hospital, Department of Gastroenterology, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[{"name":"Fujian Medical University First Affiliated Hospital, Department of Gastroenterology, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tan","family":"Tao","sequence":"additional","affiliation":[{"name":"Third People's Hospital of Hubei Province, Department of Gastroenterology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Zhang M, Jin M, Gao Z, Yu W, Zhang W. High COL10A1 expression potentially contributes to poor outcomes in gastric cancer with the help of LEF1 and Wnt2. J Clin Lab Anal 2022 Sep; 36(9): e24612;","DOI":"10.1002\/jcla.24612"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Yi Q, Zhu G, Zhu W, Wang J, Ouyang X, Yang K, Zhong J. Oncogenic mechanisms of COL10A1 in cancer and clinical challenges (Review). Oncol Rep 2024 Dec; 52(6): 162;","DOI":"10.3892\/or.2024.8821"},{"key":"ref3","unstructured":"Aktas SH, Taskin-Tok T, Al-Khafaji K, Akin-Bali DF A detailed understanding of the COL10A1 and SOX9 show better performance in the detection of early gastric cancer than in the detection of gastric cancer and advanced gastric cancer;"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Shen N, Zhu S, Zhang Z, Yong X. High Expression of COL10A1 Is an Independent Predictive Poor Prognostic Biomarker and Associated with Immune Infiltration in Advanced Gastric Cancer Microenvironment. J Oncol 2022 Oct 13; 2022: 1463316;","DOI":"10.1155\/2022\/1463316"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Liu Z, Sun L, Zhu W, Zhu J, Wu C, Peng X, Tian H, Huang C, Zhu Z. Disulfidptosis signature predicts immune microenvironment and prognosis of gastric cancer. Biol Direct 2024 Aug 15; 19(1): 65;","DOI":"10.1186\/s13062-024-00518-6"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Zhang X, Zhao Q, Tang H, Qin R, Tian T, Li C, Ma R. Laboratory biomarkers and immunological modulation of sintilimab in gastric cancer: A meta-analysis focused on tumor markers and T-cell subsets. J Med Biochem 2025; 44 (6): 1171-82;","DOI":"10.5937\/jomb0-59513"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Wang X, Bai Y, Zhang F, Li D, Chen K, Wu R, Tang Y, Wei X, Han P. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation. Front Immunol 2023 Mar 17; 14: 955949;","DOI":"10.3389\/fimmu.2023.955949"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Xie Z, Zhao W, He Y, Ke Y, Li Z, Zhang X. Mutational and transcriptional profile predicts the prognosis of stage IV gastric cancer - Prognostic factors for metastatic gastric cancer. Arab J Gastroenterol 2024 Aug; 25(3): 275-83;","DOI":"10.1016\/j.ajg.2024.05.001"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Moreira AM, Ferreira RM, Carneiro P, Figueiredo J, Osorio H, Barbosa J, Preto J, Pinto-do-0 P, Carneiro F, Seruca R. Proteomic Identification of a Gastric Tumor ECM Signature Associated With Cancer Progression. Front Mol Biosci 2022 Mar 1; 9: 818552;","DOI":"10.3389\/fmolb.2022.818552"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Wang T, Bao X, Yang F, Pan S, Xu K, Ren T. Plasma COL10A1 Level, a Potential Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. Onco Targets Ther 2024 Nov 6; 17: 949-59;","DOI":"10.2147\/OTT.S474540"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Shen W, Zhou H, Li L, Liu W, Lou Q, Tong CY, Gao J, Gao J, Shao P. Promising protein biomarkers for early gastric cancer: clinical performance of combined detection. Clin Chem Lab Med 2025 May 1;","DOI":"10.1515\/cclm-2024-1510"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV\/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY) 2021 Apr 20; 13(8): 10833-52;","DOI":"10.18632\/aging.202860"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Guo S, Wang E, Wang B, Xue Y, Kuang Y, Liu H. Comprehensive Multiomics Analyses Establish the Optimal Prognostic Model for Resectable Gastric Cancer: Prognosis Prediction for Resectable GC. Ann Surg Oncol 2024 Mar; 31(3): 2078-89;","DOI":"10.1245\/s10434-023-14249-x"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Li Y, Luo Y, Tian Q, Lai Y, Xu L, Yun H, Liang Y, Liao D, Gu R, Liu L, Yuan M, Li Y, Li Y, Lu M, Yong X, Zhang H. Integrated Bioinformatics Analysis for Identifying the Significant Genes as Poor Prognostic Markers in Gastric Adenocarcinoma. J Oncol 2022 Jun 11; 2022: 9080460;","DOI":"10.1155\/2022\/9080460"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines 2022 Sep 10; 10(9): 2248;","DOI":"10.3390\/biomedicines10092248"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hou W, Zhao Y, Zhu H. Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects. Int J Mol Sci 2023 Oct 18; 24(20): 15321;","DOI":"10.3390\/ijms242015321"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Christodoulidis G, Koumarelas KE, Kouliou MN. Revolutionising gastric cancer treatment: The potential of immunotherapy. World J Gastroenterol 2024 Jan 28; 30(4): 286-9;","DOI":"10.3748\/wjg.v30.i4.286"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines 2023 Jun 29; 11(7): 1861;","DOI":"10.3390\/biomedicines11071861"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Duan Y, Xu Y, Dou Y, Xu D. Helicobacter pylori and gastric cancer: mechanisms and new perspectives. J Hematol Oncol 2025 Jan 23; 18(1): 10;","DOI":"10.1186\/s13045-024-01654-2"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Kono K, Nakajima S, Mimura K. Biomarker-oriented chemo-immunotherapy for advanced gastric cancer. Int J Clin Oncol 2024 Jul; 29(7): 865-72;","DOI":"10.1007\/s10147-024-02525-z"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Jiang X, Zhu Z, Ding L, Du W, Pei D. ALKBH4 impedes 5-FU Sensitivity through suppressing GSDME induced pyroptosis in gastric cancer. Cell Death Dis 2024 Jun 20; 15(6): 435;","DOI":"10.1038\/s41419-024-06832-1"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Yang YN, Wang LS, Dang YQ, Ji G. Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors. World J Gastroenterol 2024 Aug 28; 30(32): 3726-9;","DOI":"10.3748\/wjg.v30.i32.3726"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs 2022 Jan 1; 33(1): e590-e603;","DOI":"10.1097\/CAD.0000000000001189"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Li J, Wu Z, Lin R. Impact of Helicobacter pylori on immunotherapy in gastric cancer. J Immunother Cancer 2024 Oct 22; 12(10): e010354;","DOI":"10.1136\/jitc-2024-010354"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Hosseini SA, Haddadi MH, Fathizadeh H, Nemati F, Aznaveh HM, Taraj F, Aghabozorgizadeh A, Gandomkar G, Bazazzadeh E. Long noncoding RNAs and gastric cancer: An update of potential biomarkers and therapeutic applications. Biomed Pharmacother 2023 Jul; 163: 114407;","DOI":"10.1016\/j.biopha.2023.114407"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Deng J, Zhang W, Xu M, Zhou J. Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy. Abdom Radiol (NY) 2023 Dec; 48(12): 3661-76;","DOI":"10.1007\/s00261-023-04046-1"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Moreno-Sanchez M, Cubiella J, Fernandez Esparrach G, Marin-Gabriel JC. Image-enhanced endoscopy in the diagnosis of gastric premalignant conditions and gastric cancer. Gastroenterol Hepatol 2023 May; 46(5): 397-409. English, Spanish;","DOI":"10.1016\/j.gastre.2022.06.008"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Diaz Del Arco C, Fernandez Acenero MJ, Ortega Medina L. Liquid biopsy for gastric cancer: Techniques, applications, and future directions. World J Gastroenterol 2024 Mar 28; 30(12): 1680-705;","DOI":"10.3748\/wjg.v30.i12.1680"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Ma Y, Jiang Z, Pan L, Zhou Y, Xia R, Liu Z, Yuan L. Current development of molecular classifications of gastric cancer based on omics (Review). Int J Oncol 2024 Sep; 65(3): 89;","DOI":"10.3892\/ijo.2024.5677"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Analiza klini\u010dke diagnosti\u010dke efikasnosti novih serumskih markera lipaze F , gastrokina 2 i kolagena tipa X \u03b11 lanca kod karcinoma \u017eeluca"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/59476\/28528","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582602301W.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:43:53Z","timestamp":1772225033000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582602301W"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-59476","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}